Table 2.

List of Clinical Samples Used for Validation Purposes

Target region	Sample name	Type	Tumor/origin	Mutation (nt)	Mutation (aa)	Estimated frequency∗
TP53 exon 8	CT20	gDNA	Colorectal cancer	c.818G>A	p.R273H	∼1%
	FC39–4	cfDNA	Esophageal cancer	c.847C>T	p.R283C	∼5%
EGFR exon 20	PT-04–09	cfDNA	Lung adenocarcinoma	c.2369C>T	p.T790M	∼0.1%
	PT-21	cfDNA	Lung adenocarcinoma	c.2369C>T	p.T790M	Wild type
	PT-04–11	cfDNA	Lung adenocarcinoma	c.2369C>T	p.T790M	∼2.1%
	PT-10–06	cfDNA	Lung adenocarcinoma	c.2369C>T	p.T790M	∼0.43%
	PT-07–16	cfDNA	Lung adenocarcinoma	c.2369C>T	p.T790M	∼2.03%
	PT-10–33	cfDNA	Lung adenocarcinoma	c.2369C>T	p.T790M	∼0.38%
	PT-04–17	cfDNA	Lung adenocarcinoma	c.2369C>T	p.T790M	∼4.08%

Circulating cell-free tumor DNA samples (cfDNA).

aa, amino acid; DNA, genomic DNA; nt, nucleotide.

^∗Mutation frequencies were estimated by previous analysis or conventional digital PCR using allele-specific probes.